COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC

The doctors review data from the COSMIC-313 trial investigating a frontline triplet therapy for advanced RCC.

EP: 1.CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes

EP: 2.CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings

EP: 3.Observing Patients with Advanced Renal Cell Carcinoma Before Systemic Therapy

EP: 4.Impact of the CLEAR Trial Data Updates in Clinical Practice

EP: 5.Approaches to the Frontline Treatment of Advanced Kidney Cancer

EP: 6.Switching a Patient with Advanced RCC Between IO + TKI and IO + IO Combination Regimens

EP: 7.Approaches to Dosing TKIs in Patients with Advanced RCC

Now Viewing

EP: 8.COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC

EP: 9.Phase III Trial of Lenvatinib, Pembrolizumab, and Belzutifan or Quavonlimab in Frontline Advanced RCC

EP: 10.Clinical Trials in Adjuvant IO Therapy for RCC

EP: 11.Disease Progression After Adjuvant Pembrolizumab Therapy for RCC

EP: 12.Frontline Therapy for Non-Clear Cell RCC

EP: 13.Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

Recent Videos

Related Content

---

Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

ONCOLOGY Staff

August 19th 2025

Article

---

Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma

August 19th 2025

Article

Related Content

---

Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

ONCOLOGY Staff

August 19th 2025

Article

---

Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma

August 19th 2025

Article